Home/Pipeline/Chitinase Inhibitor

Chitinase Inhibitor

Asthma

DiscoveryActive

Key Facts

Indication

Asthma

Phase

Discovery

Status

Active

Company

Lead Discovery Siena

About Lead Discovery Siena

Lead Discovery Siena is a private, preclinical-stage biotechnology company founded in 2015 (originating from a 2012 spin-off). It leverages a multi-faceted platform combining AI/machine learning, medicinal chemistry, and biological services to advance its own drug candidates and service client programs. The company's strategy is built on fostering local and international collaborations, with a pipeline featuring promising assets in glioblastoma and broad-spectrum antivirals, alongside a proprietary Antibody Drug Conjugate (ADC) linker technology.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases Pulmonary Diseases

Other Asthma Drugs

Drug	Company	Phase	Status
Technegas® for Asthma	Cyclomedica	Phase 2	Active
Asthma Candidate	Teva	Phase 3	Active
Montelukast Amorphous Form	Morepen Laboratories	Phase-2	Active
RIG-101	RIGImmune	Pre-clinical	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
Asthma Trial	Science 37	Phase 3	Completed/Highlighted
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Digital Biomarker for Asthma	electronRx	Early Development	Active
Flutiform	KYORIN Pharmaceutical	Marketed	Active